Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 8NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 26CNS 18Other hematologic neoplasm 15Sarcoma 14Gynecologic 7Genitourinary 5Plasma cell 2Myeloid 2Classical hematology 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 74Leucovorin 48Oxaliplatin 44Cisplatin 40Capecitabine 39Gemcitabine 37Radiotherapy 30Irinotecan 28Cetuximab 21Paclitaxel 15Bevacizumab 12Docetaxel 10Taxes 9durvalumab 8dehydroftorafur 8Surgical Procedures, Operative 8Mitomycin 8Specimen Handling 7Platinum 7Folfox protocol 7Carboplatin 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7S 1 (combination) 6Panitumumab 6Watchful Waiting 5Imatinib Mesylate 5Gene Expression Profiling 5Epirubicin 5tremelimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Granulocyte Colony-Stimulating Factor × Gastrointestinal × Clear all
NCT00069953 2017-02-17

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Radiation Therapy Oncology Group

Phase 2 Completed
43 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡